Lupin up 1.6%, launches Duloxetine 40 mg DR capsules in US

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Shares of Lupin rose 1.6 percent intraday Friday and continued to see buying interest amid weak market conditions. It says subsidiary Lupin Pharmaceuticals has launched Duloxetine 40 mg delayed-release (DR) capsule in the US.

It is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength (along with 20 mg, 30 mg and 60 mg), Lupin says.

Duloxetine capsules are used to treat major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathic pain and chronic musculoskeletal pain.

Cymbalta (one of Eli Lilly's top selling drugs) delayed-release capsules 20 mg, 30 mg and 60 mg strengths had annual US sales of approximately USD 1.05 billion, as per IMS June 2015.

At 12:27 hours IST, the scrip of Lupin was quoting at Rs 1,869.60, up Rs 6.50, or 0.35 percent on the BSE.Posted by Sunil Shankar Matkar